B2Broker Launches B2Margin White Label Margin Exchange Trading Platform
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005593/en/
Image 1: B2Margin WL Margin Exchange Trading Platform (Graphic: Business Wire)
Margin trading, long present in the Forex markets, is now hugely popular in the fast-moving crypto sphere. Even large exchanges have now implemented leveraged trading thanks to its high profit-potential which is not achievable with spot trading these days.
B2Broker CEO and Founder, Arthur Azizov comments, “Margin trading has really increased in popularity despite the fact that derivative trading is what everyone tried to avoid when this was all starting out. Back in 2016, all traders preferred spot trading but business is now moving further towards derivative trading, justifying our decision to develop B2Margin and offer an attractive margin trading solution to our clients”.
Crypto margin trading offers brokers several compelling advantages in terms of more trading opportunities. The threat of exchange hacks is also minimised since trading with leverage reduces the amount of capital that is required to be held by an exchange.
B2Margin is a White Label Margin Exchange trading platform developed by B2Broker that includes a range of functions including on-boarding, compliance, risk management, pricing and trading analytics.
Offering traders the opportunity to boost their trading with leverage, B2Margin is designed with both institutional and retail clients in mind, supporting multiple asset classes, such as FX, Metals, Indices, Energies, Stocks, ETFs, Cryptocurrencies CFDs and Spot/Cash Cryptocurrencies, with Futures Cryptocurrencies in the pipeline. This means that every broker will be able to provide two solutions to their clients - either leverage or cash trading on all the asset classes outlined.
Furthermore, B2Broker is in the final stages of completing its dividend distribution module which will allow broker-dealers to provide liquidity for STOs shares and cash equities.
Professional and Adaptive GUI
B2Margin offers a vast range of features with an advanced interface which meets all requirements from beginners to professional traders. By providing a customizable and adaptive layout, end users get to choose what they wish to see according to their needs and preferences. Trading instruments are grouped by classes with a customisable workspace which includes intuitive visualisation of market data, an extensive suite of trading tools and complete branding customisation. Some of the main features include:
Multiple Order Types
B2Margin offers multiple order types to support the most sophisticated trading strategies and provide users with a variety of options on how and when to enter and exit a trade. From Protection orders to Time in Force up to Pending orders, traders have everything they need to manage their trading activity.
This enables users to place trades, manage orders and work directly from our integrated charts and utilise a comprehensive suite of drawing tools, as well as over 50 technical indicators to analyze price trends.
The ability to withdraw, deposit and store your assets in your personal secure wallet. All assets are securely held in our offline storage system to protect users against any possible risks and threats.
Users have the opportunity to add their favourite instruments to the list and keep an eye on their current prices and 24 hour changes. Orders can then be placed straight from the Watchlist.
The list of buy and sell orders organized by price is updated in real time and is an important indicator of market depth, reflecting the trading instrument's likely price trend.
For precise risk management, a broker’s clients can set their own custom leverage for each trade order. This is a highly anticipated unique feature that provides a competitive advantage in attracting clients to a business.
Along with the standard way of managing risk known as A-Book or B-Book, B2Margin allows brokers to use C-Book - a highly advanced feature for each broker’s dealing department.
A broker dealer will also be able to customise their spread, markup, swap and commissions for each user, particular accounts and by group.
B2Broker offers all its clients 24/7 technical support.
These features, with the added benefit of detailed account statements to volume trade reports, allow brokers to get complete control over their operations and maximise their business potential.
A Complete Customised Solution in 4 Weeks
A complete B2Margin brokerage solution can be implemented in under 4 weeks once the associated legalities and financial aspects are settled. B2Margin also includes B2Broker’s client traders room solution, B2Core, which allows for client onboarding, processing deposits and withdrawals, KYC and a host of other functions for a successful Brokerage business operation. Finally, B2Margin supports FIX API connection enabling brokers to offer their clients the ultimate in trading performance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s23.7.2021 16:05:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination. “We are disappointed by the CHMP opinion. However, we remain confident in the benefit-risk profile of istradefylline and are committed to making a difference to the lives of people living with Parkinson’s, an area which has had few innovative therapies for decades,” said Abdul Mullick, President of Kyowa Kirin International. “There are currently few new treatment options available to manage end-of-dose motor fluctuations in Parkinson
ForumPay Teams Up with Bambora to Conquer the Crypto-to-Fiat Payments Market23.7.2021 15:16:00 CEST | Press release
ForumPay, an international cryptocurrency-to-fiat payment service provider, has established a partnership with the global payments provider Bambora, a Worldline brand, to bring seamless crypto payment solutions to merchants and online shoppers. The partnership will cater to a large global audience and offer expanded payment options for both shoppers and merchants. ForumPay continues its march to dominate the growing crypto payments ecosystem for merchants around the world. “ForumPay provides merchants with a seamless, secure and instant processing solution to accept payments from the more than 54 million active crypto wallet users around the world. By providing a payments service for processing crypto into fiat that functions as naturally as card payments, ForumPay enables merchants with a familiar feeling payments alternative that also gives them a competitive advantage by tapping into the fastest growing consumer base on the planet.” says Joshua Tate, CEO of ForumPay. “We are very ex
Wipro Recognized as 2021 Microsoft Modernizing Applications Partner of the Year23.7.2021 14:54:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has won the 2021 Microsoft Partner of the Year Award in the Modernizing Applications category. In addition, Wipro was also named as a category finalist in the 2021 AI Partner of the Year category, solidifying its reputation as an innovator in multiple sectors. This recognition highlights Wipro’s deep expertise and ability to go above and beyond for its customers, powered by an established partnership with Microsoft. Even when working with complex customer environments, spanning across hundreds of servers with different applications of different versions, Wipro was able to help customers meet their business needs and leverage the power of public cloud in an efficient way. “Global enterprises have embraced modernization at an unprecedented scale and pace, and the demands of the past year show no sign of easing. We are honor
Merck Announces Appointment of Head of China & International for Healthcare23.7.2021 13:45:00 CEST | Press release
Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will lead China, Japan as well the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, the franchise of Cardiovascular Metabolism & Endocrinology (CM&E), and the Global Business Innovation team. Chow will report to Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare. She will serve as a member of the Healthcare Executive Committee, and be based in Shanghai, China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210723005186/en/ Merck Announces Appointment of Head of China & International for Healthcare (Photo: Business Wire) “Hong’s international experience and strong track record of bringing innovative medicines to patients in need across both developed and emerging markets, most nota
H.I.G. WhiteHorse Refinances Grupo Recoletas23.7.2021 13:03:00 CEST | Press release
H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a refinancing package for Grupo Hospitalario Recoletas (“Recoletas”), which includes a significant growth capital component. Recoletas is a family-owned Spanish private hospital operator headquartered in Valladolid, Spain, with a leading position in the Castilla y Leon Spanish inland region. It operates 8 hospitals with c. 540 beds and 13 medical centres across 7 regions. H.I.G. WhiteHorse has committed €110 million in unitranche loans to refinance the borrower's existing indebtedness and provide additional capital to finance growth, supporting the Company’s expansion. Recoletas is currently developing ambitious projects to expand its healthcare services provided through hospitals and medical centers, as well as diagnostic imaging centers and radiotherapy units. Amando J. Rodríguez, President and CEO of Grupo Hospitalario Recoletas, said: “We are very ha
Schlumberger Announces Second-Quarter 2021 Results23.7.2021 12:50:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second-quarter 2021. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2021Mar. 31, 2021Jun. 30, 2020SequentialYear-on-yearRevenue* $5,634 $5,223 $5,356 8% 5% Income (loss) before taxes - GAAP basis $542 $386 $(3,627) 40% n/m Net income (loss) - GAAP basis $431 $299 $(3,434) 44% n/m Diluted EPS (loss per share) - GAAP basis $0.30 $0.21 $(2.47) 43% n/m Adjusted EBITDA** $1,198 $1,049 $838 14% 43% Adjusted EBITDA margin** 21.3% 20.1% 15.6% 118 bps 561 bps Pretax segment operating income** $807 $664 $396 22% 104% Pretax segment operating margin** 14.3% 12.7% 7.4% 162 bps 694 bps Net income, excluding charges & credits** $431 $299 $69 44% 525% Diluted EPS, excluding charges & credits** $0.30 $0.21 $0.05 43% 500% Revenue by Geography International $4,511 $4,211 $4,224 7% 7% North America* 1,083 972 1,097 11% -1% Other 40 40 35 n/m n/m $5,634 $5,223 $5,356 8% 5% *Schlumberger di
Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm23.7.2021 11:59:00 CEST | Press release
The Wyss Center and Artiria Medical today announced a new partnership to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. Artiria Medical, an early-stage medical device company focused on disruptive neurovascular products, has been developing the technology and is now joining forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. The team has received support from the Swiss Innovation Agency, Innosuisse, to test and validate the efficacy of the therapy preclinically, in preparation for human clinical studies. Stroke is the third leading cause of disability worldwide with more than 80 million people living with long-term impairments as a result. Some strokes result in bleeding in the brain. Such hemorrhagic strokes can lead to severe cerebral vasospasm - an uncontrolled contraction of brain arteries - in the days that follow, depriving